Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 28;56(4):1573-82.
doi: 10.1021/jm3013882. Epub 2013 Feb 12.

Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly

Affiliations

Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly

Shu Liu et al. J Med Chem. .

Abstract

A major challenge in drug discovery is to develop and improve methods for targeting protein-protein interactions. Further exemplification of the REPLACE (REplacement with Partial Ligand Alternatives through Computational Enrichment) strategy for generating inhibitors of protein-protein interactions demonstrated that it can be used to optimize fragment alternatives of key determinants, to combine these in an effective way, and this was achieved for compounds targeting the cyclin-dependent kinase 2 (CDK2) substrate recruitment site on the cyclin regulatory subunit. Phenylheterocyclic isosteres replacing a critical charge-charge interaction provided new structural insights for binding to the cyclin groove. In particular, these results shed light onto the key contributions of a H-bond observed in crystal structures of N-terminally capped peptides. Furthermore, the structure-activity relationship of a bis(aryl) ether C-terminal capping group mimicking dipeptide interactions was probed through ring substitutions, allowing increased complementarity with the primary hydrophobic pocket. This study further validates REPLACE as an effective strategy for converting peptidic compounds to more pharmaceutically relevant compounds.

PubMed Disclaimer

Conflict of interest statement

Notes: The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
REPLACE mediated conversion of the octapeptide cyclin groove inhibitor HAKRRLIF into an N and C-terminally capped dipeptide. (Structures were modeled from PDB ID 2UUE).
Figure 2
Figure 2
Modeled structure of SCCP5773 in complex with CDK4/cyclin D1 (brown carbon atoms) overlayed with the crystal structure of the same Ncap bound to CDK2/cyclin A2 (yellow carbon atoms). A Connolly surface representation of cyclin A is shown along with the putative water molecule contributing bridging hydrogen bonds.
Scheme 1
Scheme 1
Synthesis of phenyltriazole N-capping groups
Scheme 2
Scheme 2
Synthesis of phenylpyrazole N-capping groups
Scheme 3
Scheme 3
Synthesis of phenylfuran N-capping groups
Scheme 4
Scheme 4
Synthesis of phenylpyrrole N-capping groups
Scheme 5
Scheme 5
Synthesis of phenylimidazole N-capping groups

Similar articles

Cited by

References

    1. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–1677. - PubMed
    1. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nature Reviews Cancer. 2001;1:222–231. - PubMed
    1. McInnes C, Andrews MJI, Zheleva DI, Lane DP, Fischer PM. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Current Medicinal Chemistry-Anti-Cancer Agents. 2003;3:57–69. - PubMed
    1. Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. Journal Of Cellular Physiology. 2002;190:160–169. - PubMed
    1. Zheleva DI, McInnes C, Gavine AL, Zhelev NZ, Fischer PM, Lane DP. Highly potent p21WAF1 derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. Journal of Peptide Research. 2002;60:257–270. - PubMed

Publication types

MeSH terms